高新興(300098.SZ):實控人劉雙廣近期通過大宗交易減持2655.52萬股
格隆匯 9 月 21日丨高新興(300098.SZ)公佈,2020年9月21日,公司接到劉雙廣函告,近期其通過大宗交易的方式合計減持了高新興2655.52萬股股份,佔高新興總股本的1.51%。此次交易完成後,信息披露義務人劉雙廣及其一致行動人石河子網維投資普通合夥企業(“石河子網維”)擁有的權益自2018年11月披露權益變動報告書以來累計減少比例達到公司已發行股份的5%。
此次減持後,劉雙廣直接持有高新興股份447,908,857股,佔公司總股本的25.51%,仍為公司的控股股東、實際控制人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.